10-K: Dermata Therapeutics Pivots to DTC Skincare Amid Losses

Dermata Therapeutics shifts focus from prescription drugs to direct-to-consumer and B2B skincare products, reporting continued losses and a going concern warning.

Summary

• Dermata Therapeutics has strategically shifted its business model from developing prescription (Rx) products to developing and distributing direct-to-consumer (DTC) and business-to-business (B2B) skincare products.
• The company achieved statistically significant Phase 3 STAR-1 clinical trial results for its former lead Rx candidate, XYNGARI (DMT310), for moderate-to-severe acne in March 2025, but subsequently decided to pivot due to market trends and high Rx development/commercialization costs.
• The new brand, 'Tome,' will launch its first cosmetic product, 'Foundational Treatment' (powered by Bioneedle), in mid-2026, followed shortly by an OTC acne product, 'Clearing Treatment' (combining Bioneedle with salicylic acid).
• The company reported a net loss of approximately $7.6 million for the year ended December 31, 2025, an improvement from $12.3 million in 2024.
• As of December 31, 2025, cash and cash equivalents totaled $7.5 million, with an accumulated deficit of $73.2 million.
• The independent registered public accounting firm included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Research and development expenses decreased by approximately $5.3 million in 2025, primarily due to the completion of the STAR-1 acne study and the strategic pivot.
• Selling, general and administrative expenses increased by approximately $0.5 million in 2025, driven by $0.7 million in marketing expenses related to the new brand launch.
• The company relies on a single, exclusive supplier in Russia for its key ingredient, Spongilla lacustris, which poses geopolitical and supply chain risks.
• Dermata plans to leverage its Bioneedle technology for intradermal delivery of macromolecules like botulinum toxin for aesthetic and medical conditions, with a Phase 2a clinical trial for axillary hyperhidrosis currently on hold.
• The company terminated its license agreement with Villani, Inc. effective February 15, 2026, following a dispute over the strategic shift.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the significant 'going concern' warning, continued substantial losses, and the inherent risks of a strategic pivot for a pre-commercial company, despite the potential upside of the new market focus and recent capital raises.

Positives

• Achieved statistically significant results in Phase 3 STAR-1 clinical trial for XYNGARI (DMT310) for moderate-to-severe acne in March 2025, demonstrating efficacy across all three co-primary endpoints.
• Strategic pivot to DTC and B2B skincare products is expected to accelerate path to commercialization, reduce regulatory burden, and decrease development expenses.
• The 'Tome' brand aims to leverage the company's clinical knowledge to create effective and safe skincare products accessible without a prescription.
• The 'Bioneedle' technology, derived from Spongilla lacustris, offers unique mechanical and organic properties for skin exfoliation, microchannel creation, and potential collagen production.
• The company has an exclusive supply agreement with a Russian supplier for Spongilla lacustris, ensuring a source for its hero ingredient, with recent shipments providing sufficient quantities for initial product launches.
• Net loss decreased to $7.6 million in 2025 from $12.3 million in 2024, indicating reduced operating losses.
• Successful capital raises in January 2025 ($2.2 million net), March 2025 ($5.7 million net), and December 2025 ($3.8 million net), along with ATM sales, provided $12.1 million in financing activities for 2025.
• The company has a robust intellectual property portfolio with patents and applications covering its Clearing Treatment, Bioneedle Delivery System for botulinum toxin, and other large molecules, with expected expiration dates in 2039-2041.

Negatives

• The company is a pre-commercial stage company with a limited operating history and has never launched a commercial product, introducing significant execution risk.
• Incurred substantial net losses since inception, with an accumulated deficit of $73.2 million as of December 31, 2025.
• The independent registered public accounting firm's report contains an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Requires significant additional capital to fund operations and commercialization efforts, with existing cash expected to last only into the first quarter of 2027.
• Reliance on a single, exclusive supplier (Reka-Farm LLC in Russia) for Spongilla raw material exposes the company to geopolitical risks, supply chain disruptions, and potential contamination.
• The strategic shift to OTC/cosmetics introduces new regulatory risks, including potential FDA challenges to product classification or claims, which could delay launches or require costly reformulations.
• The skincare industry is highly competitive, with many large multinational companies having greater resources, brand recognition, and marketing experience.
• The Phase 2a clinical trial for topical botulinum toxin delivery (BDS) in collaboration with Revance Therapeutics, Inc. has been placed on hold, delaying a potential revenue stream.
• Termination of the license agreement with Villani, Inc. could lead to disputes regarding post-termination obligations, intellectual property, and potential claims, incurring legal costs and management distraction.
• Low brand awareness compared to established skincare brands, requiring substantial marketing investment with no guarantee of success.
• The company's ability to use its net operating loss carryforwards (NOLs) of $31.6 million (federal) and $5.0 million (state) may be limited by Section 382 of the Internal Revenue Code due to potential ownership changes.

Risks

• The skincare industry is highly competitive, and if unable to compete effectively, results will suffer.
• Lack of operating history as a commercial company and no prior commercial product launches.
• History of net losses and anticipation of future losses.
• Current and future capital requirements to support development and commercialization efforts, and ability to satisfy capital needs.
• Dependence on products still in various stages of development and pre-commercial launch.
• Ability to acquire sufficient quantities of raw material needed to manufacture products.
• Ability of third-party manufacturers to produce cGMP quantities of product ingredients for consumer use studies and commercial quantities.
• Possibility that planned OTC formulation, dosage, combination, or indications fall outside applicable OTC monographs, require new drug applications (NDA), or are challenged by regulators.
• Possibility that positive clinical data from Rx setting are not predictive of consumer experience or commercial performance in OTC context, limiting permissible OTC claims.
• Ability to timely secure and scale manufacturing, packaging, and quality systems suitable for commercialization, and to manage product returns, recalls, or withdrawals.
• Ability to establish and maintain distribution and sales channels (DTC e-commerce, B2B professional/clinic, retail partners) and manage channel economics.
• Maintenance of a single source for sponge raw material; business and operating results could be harmed if supply is restricted, ceases, or prices increase.
• Ability to internally develop new inventions and intellectual property.
• Interpretations of current laws and the passage of future laws.
• Impacts of increased trade tariffs, import quotas, or other trade restrictions, including potential changes in U.S. trade policies.
• Acceptance of the business model by investors.
• Accuracy of estimates regarding expenses and capital requirements.
• Ability to adequately support organizational and business growth.
• Disruptions in the global economy and supply chains may have a material adverse effect.
• Adverse global conditions, including economic uncertainty, may negatively impact financial results.
• Damage to reputation or brand may materially and adversely affect the business.
• Success depends on the quality, efficacy, and safety of products; any loss of consumer confidence could tarnish the brand.
• Illegal distribution and sale of counterfeit products or unauthorized diversion could harm net sales and reputation.
• Demand for products may not increase as rapidly as anticipated due to economic conditions and resistance to non-traditional treatment methods.
• Declines in average selling prices of products may decrease net revenues.
• Inability to successfully implement growth strategy.
• Growth and profitability are dependent on a number of factors, and inability to sustain profitability.
• Inability to grow business effectively or efficiently.
• Acquisitions or investments could disrupt business and harm financial condition.
• Future quarterly and annual operating results are expected to fluctuate significantly.
• A disruption in operations could materially and adversely affect the business.
• Dependence on retention of key senior management and ability to attract and retain qualified personnel.
• Reliance on third-party suppliers, distributors, and other vendors who may fail to meet standards or regulatory requirements.
• Business may be affected by new sanctions, import restrictions, and export controls targeting Russia.
• Reliance on third-party delivery service providers; interruptions or failures could prevent timely delivery.
• A disruption in the operations of primary freight carrier or higher shipping costs could cause a decline in net revenues or earnings.
• Failure to manage inventory effectively could materially and adversely affect results.
• Substantial cash spending on marketing activities may not prove successful.
• Skincare professionals may not be obligated to purchase products, and business challenges at providers could adversely affect results.
• Consumer use studies and product testing involve inherent risks, including adverse skin reactions, negative publicity, and regulatory scrutiny.
• Collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships may not result in commercially viable products or significant revenues.
• New laws, regulations, enforcement trends, or changes in existing regulations governing product introduction, marketing, and sale could harm the business.
• Extensive and continuing regulatory compliance obligations; failure to obtain and maintain market clearances or comply with requirements could harm commercial operations.
• Government regulations and private party actions relating to marketing and advertising may restrict ability to sell products.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Increasing cost and difficulty of compliance with healthcare regulations may impede business growth.
• Marketing products in violation of healthcare laws may lead to civil or criminal penalties.
• Evolving government regulation of the Internet and e-commerce; unfavorable changes or non-compliance could harm the business.
• Products may cause undesirable side effects or have other unexpected properties, limiting commercial appeal or resulting in regulatory action.
• Product liability exposure; inadequate insurance coverage could result in substantial liability.
• Improper promotion or off-label use of products by physicians could lead to prohibitions on sale, product liability claims, and significant fines.
• Decision not to continue developing or commercializing products at any time would reduce or eliminate potential return on investment.
• Product recalls in the future could harm brand and reputation.
• Employees, independent contractors, consultants, vendors, CROs, and partners may engage in misconduct or improper activities.
• Future growth depends on ability to penetrate foreign markets, subject to additional regulatory burdens and risks.
• Use of social media may materially and adversely affect reputation or subject to fines.
• Reliance on email and other messaging services; restrictions or inability to deliver communications could adversely affect net revenue.
• Need to further increase size and complexity of organization; difficulties in executing growth strategy and managing growth.
• Failure to attract and retain management and other key personnel.
• Limited marketing capabilities; inability to establish sales and marketing capabilities on own or through third parties.
• Failure to successfully in-license, acquire, develop, and market additional products would impair ability to grow.
• Operating results may fluctuate significantly, making future results difficult to predict.
• Operating results and liquidity needs could be negatively affected by market fluctuations and economic downturn.
• Failures in internal computer systems could harm business.
• Increasing dependence on information technology, cybersecurity, and data leakage risks.
• Increasing use of artificial intelligence (AI) may create operational, compliance, and reputational risks.
• Inability to obtain or enforce patent rights or other intellectual property rights of sufficient breadth.
• Proprietary trade secrets and unpatented know-how may not be adequately protected.
• Recent patent reform legislation could increase uncertainties and costs surrounding patent prosecution and enforcement.
• Inability to protect intellectual property rights throughout the world.
• Obtaining and maintaining patent protection depends on compliance with various procedural requirements.
• Being sued for infringing intellectual property rights of third parties would be costly and time-consuming.
• Involvement in lawsuits to protect or enforce patents or other intellectual property could be expensive and time-consuming.
• Reliance on third parties requires sharing trade secrets, increasing risk of misappropriation.
• Subject to claims that employees, consultants, or independent contractors have wrongfully used or disclosed alleged trade secrets of former employers.
• Patent term expiration before or soon after products are available for sale, or successful challenges to patents by generic manufacturers, could harm business.
• Inadequate protection of trademarks and trade names could hinder name recognition.
• Proprietary information may be lost, or security breaches may occur.
• Termination of license agreement with Villani could negatively impact operations.
• Market price of common stock and Warrants has been volatile and can fluctuate substantially.
• Warrants may not have any value.
• Ability to use net operating loss carryforwards may be limited.
• Never paid dividends and do not anticipate paying any in the foreseeable future.
• Designation of Delaware Court of Chancery as exclusive forum for certain actions could limit stockholders' ability to obtain favorable judicial forum.

Future Outlook

The company plans to launch its first cosmetic product, 'Tome Foundational Treatment,' in mid-2026, followed shortly by its first OTC acne product, 'Tome Clearing Treatment.' It intends to expand its product line with additional OTC and cosmetic offerings leveraging its Bioneedle technology for various skin conditions and aesthetic applications. The company also aims to build a network of certified skincare professionals and explore partnerships for global commercialization. Management anticipates continued net losses for at least the next twelve months and expects selling, general, and administrative expenses to increase due to marketing and personnel costs.

Management Comments

• "We believe this strategic repositioning will accelerate our path to commercialization, reduce our regulatory burden, and decrease development expenses, all while enabling us to address broad consumer segments in the skincare market."
• "We believe that if we can provide consumers with a unique topical acne treatment, we have an opportunity to capture a large segment of acne patients prior to them seeking Rx products through a physician."
• "We plan to launch our first cosmetic product in the middle of 2026, with our first OTC acne product to follow shortly thereafter."
• "We believe our Bioneedle is differentiated by enabling the delivery of both small and large molecules through topical application with less irritation and side effects than other topically applied products."
• "We believe our avid skincare users have a true fascination with their skin, and thus, are in pursuit of knowledge about the best products available. We believe we can immerse our consumers in our products and especially our hero ingredient, because it truly is one of a kind. Which is why we have branded our new skincare line Tome."
• "We believe our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2027."

Industry Context

StockSavvy.ai notes that Dermata Therapeutics' strategic pivot into the DTC and B2B skincare market aligns with broader industry trends favoring natural ingredients, science-backed formulations, and simplified, multifunctional routines. The increasing consumer willingness to self-treat common skin conditions with OTC products, coupled with difficulties in accessing dermatologists and high Rx costs, creates a fertile ground for innovative OTC offerings. The global cosmetic and skincare market, projected to reach $736 billion by 2028, indicates significant growth potential. However, this market is also highly competitive, with established multinational players and emerging digital-first brands. Dermata's emphasis on its unique 'Bioneedle' ingredient and a dual-channel marketing strategy (DTC and professional) is a common approach for new entrants seeking differentiation and credibility in a crowded space.

Comparison to Industry Standards

• The company's shift from Rx to OTC/cosmetics is a significant departure from traditional pharmaceutical development, which typically involves lengthy and costly FDA approval processes. This move aims for faster time-to-market and reduced regulatory burden compared to Rx-focused peers.
• The target market for OTC acne products, with over 50 million U.S. patients and 70% trying OTC first, is substantial, comparable to the broad reach of established brands like Neutrogena, Proactiv, and Clean & Clear.
• Dermata's 'once-weekly' application for its Foundational Treatment and Clearing Treatment aims to differentiate from many existing OTC products that require daily or multiple daily applications, addressing a common patient compliance issue in the market.
• The use of 'Bioneedle' (Spongilla lacustris) as a 'hero ingredient' for mechanical exfoliation and microchannel creation is a novel approach compared to traditional OTC actives like salicylic acid or benzoyl peroxide, which often have tolerability issues.
• The company's dual-channel marketing strategy (DTC and B2B professional) is similar to hybrid models adopted by some 'cosmeceutical' brands that bridge the gap between traditional cosmetics and therapeutic skincare, seeking both broad consumer reach and professional endorsement.
• The 'going concern' warning and accumulated deficit of $73.2 million are typical for pre-commercial biotechnology companies but highlight significant financial risk compared to profitable, established skincare brands.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material pending litigation or aware of any threatened material legal proceedings.
• Received a notice of material breach and demand for cure from Villani, Inc. on November 10, 2025, alleging failure to use commercially reasonable efforts for prescription products, failure to provide advance notice of submissions, and use of licensed know-how outside the defined field.
• Received an additional notice from Villani, Inc. on November 11, 2025, requesting reversion and assignment of assets, preservation of inventory, and preservation of documents related to Spongilla.
• The company disputes Villani's allegations and terminated the license agreement effective February 15, 2026.

Related Party Transactions

• Sean Proehl, son of CEO Gerald T. Proehl, is employed as General Counsel with an annual salary of $260,000.
• Entered into a Master Services Agreement in September 2025 with Wilder & Partners, LLC, an agency assisting with branding, marketing, and product design. The founding partner of Wilder is the CEO's son-in-law. Approximately $0.6 million in marketing expenses were incurred in 2025, with $0.1 million outstanding.
• Gerald T. Proehl (CEO) and Mary Fisher (Director) participated in the January 2025 Private Placement, purchasing shares and warrants for $1,000,000.54 and $250,000.77, respectively. Other insiders (Kyri K. Van Hoose, David F. Hale, Sean Proehl) also participated for less than $120,000 each.
• Gerald T. Proehl (through Proehl Family Trust and Sean Michael Proehl Irrevocable Trust) and Kyri K. Van Hoose (CFO) participated in the December 2025 Private Placement, purchasing shares and warrants for an aggregate of $1.25 million and $250,000, respectively.
• In connection with the December 2025 PIPE, certain insiders (including Gerald T. Proehl, Kyri K. Van Hoose, and Sean M. Proehl) agreed to amend outstanding January 2025 Warrants to reduce the exercise price from $12.70 to $2.04 per share, subject to stockholder approval.

Stakeholder Impact

• **Shareholders:** Face substantial dilution risk from future equity financings and potential loss of investment due to the 'going concern' uncertainty and pre-commercial stage of the company. The strategic pivot aims for faster commercialization and potentially greater financial upside, but introduces new market and regulatory risks. Anti-takeover provisions may limit opportunities for a premium on shares.
• **Employees:** The company's future success depends on attracting and retaining qualified personnel. Incentive compensation plans and equity-based grants are used for retention. The strategic shift may alter job roles and skill requirements.
• **Customers (DTC Consumers & B2B Professionals):** Will gain access to new 'Tome' skincare products, including a foundational treatment and an acne system, leveraging the 'Bioneedle' technology. The dual-channel strategy aims to provide flexibility in access and professional endorsement. Product quality, efficacy, and safety are critical for customer satisfaction and brand loyalty.
• **Suppliers:** The exclusive supply agreement with Reka-Farm LLC (Russia) for Spongilla raw material creates a critical dependency, exposing the company to geopolitical and supply chain risks that could impact product availability.
• **Creditors:** The 'going concern' warning indicates heightened risk regarding the company's ability to meet its financial obligations, potentially impacting future credit terms or availability.

Next Steps

• Launch 'Tome Foundational Treatment' (cosmetic product) in mid-2026.
• Launch 'Tome Clearing Treatment' (OTC acne product) shortly after the Foundational Treatment.
• Initiate a user marketing study in the near term.
• Continue research and development on additional skincare products for future launches.
• Manufacture products for commercial sale.
• Hire additional marketing, general, and administrative personnel.
• Maintain, expand, and protect the intellectual property portfolio.
• Evaluate alternative manufacturing sources for Spongilla raw material.
• Continue discussions with Revance Therapeutics, Inc. regarding future opportunities for the Bioneedle Delivery System collaboration.
• Seek additional capital through public or private equity/debt financings or other sources to fund operations beyond Q1 2027.
• Build a network of certified skincare professionals through a 'Tome certification program'.
• Explore partnerships and distribution agreements for global commercialization.

Key Dates

Recommendation

Dermata Therapeutics presents a high-risk, high-reward scenario. The strategic pivot from Rx to DTC/B2B skincare, leveraging the unique 'Bioneedle' ingredient, offers a potentially faster path to commercialization and addresses a large market. The positive Phase 3 data for the former Rx candidate suggests underlying scientific merit. However, the company's 'going concern' warning, history of significant losses, and reliance on a single, geopolitically sensitive supplier for its core ingredient introduce substantial financial and operational risks. While recent capital raises provide some liquidity, the need for further financing is imminent. The stock is speculative, and while the new strategy has potential, the execution risks and financial instability warrant a 'hold' recommendation for seasoned investors, advising caution and close monitoring of product launches, market acceptance, and financial health before considering further investment.

Keywords

Dermata Therapeutics, Skincare, DTC, B2B, Spongilla lacustris, Bioneedle, Acne Treatment, Cosmetics, OTC Products, Pharmaceuticals, Biotechnology, SEC Filing, 10-K, Financial Reporting, Going Concern, Capital Raise, Intellectual Property, Regulatory Compliance, Nasdaq